A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia

Joseph P. McEvoy, David G. Daniel, William H. Carson, Robert D. McQuade, Ronald N. Marcus

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia'. Together they form a unique fingerprint.

Medicine & Life Sciences